Get Real USA, Inc. (OTCMKTS:GTRL) stock has lost in oblivion and the big reason behind this poor performance is lack of updates coming from the company. In January press release the company updated on the sales recorded in December.
Get Real reported that it recorded strong sales in the month of December. The CEO, Thomas Beener, said that they are extremely delighted with the sales numbers, which continues to increase at considerable monthly rates. Sales figure for the December month was projected to surpass $200,000, which indicates a 68% growth from November sales figure of $119,000. However, since then there has been no update coming from the company.
Since inception in last June, the sales have increased in June 2015 from $1,000 to $12,000 in July 2015.The sales figure in August stood at $52,000 while it jumped to $90,000 and $115,000 in September and October, respectively.
The experts speak
The CEO of Get Real said that December month’s sales performance is a big step from the recently announced quarterly report for quarter closed October. The team continues to outperform and that is seen in both company’s corporate culture and sales numbers. Beener added that they continue to pursue the objective of excelling in the market compared to other micro- cap firms by providing investors with transparency and record actual revenue.
Get Real reported that despite this positive news, they also want to update that the company at this time is trying to resolve conflicts with Amazon.com, Inc. (NASDAQ:AMZN). The online seller has taken various steps that have led in the suspension of company’s sales and shipping. Now, they are actively taking measures to resolve the conflict, but are not sure if they can find the solution anytime soon in coming period. It should be noted that company’s main business objective is the selling of electronic products through Amazon.com.
OXIS International, Inc. (OTCMKTS:OXIS) Facing Uncertain Future As Bears Take Control
OXIS International, Inc. (OTCMKTS:OXIS) sentiments on the street have turned sour if a recent downturn is anything to go by. The stock continues to trade on the red, threatening to break below its trading range of between $0.15-0.19 a share.
The downturn comes even on the company acquiring rights for the development and marketing of a new technology for targeting cancer cells. The acquisition of Trispecific Killer Engager according to CEO, Anthony J Cataldo, provides the company a new proven asset as the race to come up with breakthroughs on cancer treatments heats up.
OXIS International, Inc. (OTCMKTS:OXIS) has also registered positive clinical trials for its lead candidate drug OXS-1550 as it continues to work on other cancer initiatives. The fact that the microcap is little known on the street could be one of the reasons it continues to trade lower given the huge upside potential at stake with the current robust pipeline of drugs.